Second, considering the genetic heterogeneity of colorectal cancers[28,29], the absence of detectable KRAS mutations in the primary tumor may not formally exclude the presence of a KRAS mutation in metastases, and consequently, additional tumor samples need to be examined in order for KRAS mutations to correctly predict the KRAS status in metastatic lesions. This evidence concerns the gene KRAS and colorectal cancer.